ARTV · Artiva Biotherapeutics, Inc. · Executive Compensation
$7.13
+0.30 (+4.39%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$344.19M
Shares
48.89M
Volume · Oct 5
473.19K
Avg daily vol (3M)
406.14K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Fred Aslan | Chief Executive Officer | $6,671,215 |
| Jennifer Bush | Chief Operating Officer, Chief Legal Officer and Compliance Officer | $1,536,715 |
| Christopher P. Horan | Chief Technical Operations Officer | $1,415,855 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Fred Aslan | Chief Executive Officer | $7,827,788 |
| Jennifer Bush | Chief Operating Officer, Chief Legal Officer and Compliance Officer | $1,505,839 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Laura Stoppel, Ph.D. | Class II director | Appointed | 2026-09-11 |
| Brian Daniels, M.D. | Class II director | Appointed | 2026-09-11 |
| Fred Aslan, M.D. | principal financial officer and principal accounting officer | Appointed | 2026-05-19 |
| Fred Aslan, M.D. | President | Resigned | 2026-05-19 |
| Diego Miralles, M.D. | President and Head of Research and Development | Appointed | 2026-05-19 |
| Diego Miralles, M.D. | member of the Board of Directors | Resigned | 2026-05-19 |
| Thad Huston | Chief Financial Officer | Appointed | 2026-02-24 |
| Elaine Sorg | Class I director | Appointed | 2026-02-19 |
| Daniel Baker, Ph.D. | Class I director | Appointed | 2025-06-25 |
| Brian Daniels, M.D. | member of the Clinical Strategy Committee | Appointed | 2025-01-29 |
| Laural Stoppel, Ph.D. | member of the Clinical Strategy Committee | Appointed | 2025-01-29 |
| Diego Miralles, M.D. | chair of the Clinical Strategy Committee | Appointed | 2025-01-29 |
| Daniel Baker, Ph.D. | member of the Clinical Strategy Committee of the Board | Appointed | 2025-01-29 |
| Laura Bessen, M.D. | member of the Clinical Strategy Committee | Appointed | 2025-01-29 |
| Daniel Baker, Ph.D. | Class I director | Appointed | 2025-01-29 |
| Alison Moore, Ph.D. | Class III director | Appointed | 2024-10-22 |